Biomarkertest zur Vorhersage oder Früherkennung von Präeklampsie Und/oder Hellp-Syndrom
Anmelder: Genesis Theranostix Korlatolt Felelossegu Tarsasag, Semmelweis University, The United States of America, As Represented by the Secretary, Dept. of Health & Human Services Office of Technology Transfer, Wayne State University 🇭🇺
Details
- Veröffentlichungs-Nr.
- EP3339861
- Aktenzeichen
- EP18154812
- Anmeldetag
- 13. Juni 2013
- Veröffentlichung
- 1. November 2023
- Erteilung
- 1. November 2023
- Rechtsraum
- EP
- IPC
- G01N33/53C12Q1/00G01N33/68
Abstract
The present disclosure provides a test which can be used to predict and/or detect preeclampsia and/or Haemolysis, Elevated Liver enzymes and Low Platelets (HELLP) syndrome in pregnant women. More specifically, the disclosure provides a panel of biomarkers that can be used for early prediction and/or detection of preeclampsia and/or HELLP syndrome and may also allow the prediction and detection of closely related complications of pregnancy in early gestation such as including but not limited to implantation failure, and threatened and spontaneous miscarriage.
Anmelder
- Firmen
- Genesis Theranostix Korlatolt Felelossegu Tarsasag
Semmelweis University
The United States of America, As Represented by the Secretary, Dept. of Health & Human Services Office of Technology Transfer
Wayne State University - Land
- 🇭🇺 Ungarn